vs
CareDx, Inc.（CDNA）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是CareDx, Inc.的1.7倍（$200.5M vs $117.7M），CareDx, Inc.净利率更高（2.4% vs 2.2%，领先0.1%），CareDx, Inc.同比增速更快（39.0% vs 5.2%），ROGERS CORP自由现金流更多（$1.1M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -3.3%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
CDNA vs ROG — 直观对比
营收规模更大
ROG
是对方的1.7倍
$117.7M
营收增速更快
CDNA
高出33.7%
5.2%
净利率更高
CDNA
高出0.1%
2.2%
自由现金流更多
ROG
多$586.0K
$514.0K
两年增速更快
CDNA
近两年复合增速
-3.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $200.5M |
| 净利润 | $2.8M | $4.5M |
| 毛利率 | — | 32.2% |
| 营业利润率 | 1.0% | — |
| 净利率 | 2.4% | 2.2% |
| 营收同比 | 39.0% | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.05 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAROG
| Q1 26 | $117.7M | $200.5M | ||
| Q4 25 | $108.4M | $201.5M | ||
| Q3 25 | $100.1M | $216.0M | ||
| Q2 25 | $86.7M | $202.8M | ||
| Q1 25 | $84.7M | $190.5M | ||
| Q4 24 | $86.6M | $192.2M | ||
| Q3 24 | $82.9M | $210.3M | ||
| Q2 24 | $92.3M | $214.2M |
净利润CDNAROG
| Q1 26 | $2.8M | $4.5M | ||
| Q4 25 | $-4.1M | $4.6M | ||
| Q3 25 | $1.7M | $8.6M | ||
| Q2 25 | $-8.6M | $-73.6M | ||
| Q1 25 | $-10.4M | $-1.4M | ||
| Q4 24 | $87.7M | $-500.0K | ||
| Q3 24 | $-10.6M | $10.7M | ||
| Q2 24 | $-4.6M | $8.1M |
毛利率CDNAROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 31.6% | ||
| Q1 25 | — | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率CDNAROG
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 3.5% | ||
| Q3 25 | -0.2% | 7.3% | ||
| Q2 25 | -12.8% | -33.3% | ||
| Q1 25 | -15.8% | -0.2% | ||
| Q4 24 | 97.5% | -6.6% | ||
| Q3 24 | -16.6% | 6.9% | ||
| Q2 24 | -7.9% | 5.3% |
净利率CDNAROG
| Q1 26 | 2.4% | 2.2% | ||
| Q4 25 | -3.8% | 2.3% | ||
| Q3 25 | 1.7% | 4.0% | ||
| Q2 25 | -9.9% | -36.3% | ||
| Q1 25 | -12.2% | -0.7% | ||
| Q4 24 | 101.3% | -0.3% | ||
| Q3 24 | -12.8% | 5.1% | ||
| Q2 24 | -5.0% | 3.8% |
每股收益（稀释后）CDNAROG
| Q1 26 | $0.05 | $0.25 | ||
| Q4 25 | $-0.08 | $0.20 | ||
| Q3 25 | $0.03 | $0.48 | ||
| Q2 25 | $-0.16 | $-4.00 | ||
| Q1 25 | $-0.19 | $-0.08 | ||
| Q4 24 | $1.60 | $-0.04 | ||
| Q3 24 | $-0.20 | $0.58 | ||
| Q2 24 | $-0.09 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.2B |
| 总资产 | $411.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNAROG
| Q1 26 | $77.9M | $195.8M | ||
| Q4 25 | $177.2M | $197.0M | ||
| Q3 25 | $194.2M | $167.8M | ||
| Q2 25 | $186.3M | $157.2M | ||
| Q1 25 | $230.9M | $175.6M | ||
| Q4 24 | $260.7M | $159.8M | ||
| Q3 24 | $240.9M | $146.4M | ||
| Q2 24 | $228.9M | $119.9M |
总债务CDNAROG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNAROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $303.1M | $1.2B | ||
| Q3 25 | $311.1M | $1.2B | ||
| Q2 25 | $327.4M | $1.2B | ||
| Q1 25 | $379.3M | $1.3B | ||
| Q4 24 | $378.4M | $1.3B | ||
| Q3 24 | $273.2M | $1.3B | ||
| Q2 24 | $264.7M | $1.3B |
总资产CDNAROG
| Q1 26 | $411.1M | $1.4B | ||
| Q4 25 | $413.2M | $1.4B | ||
| Q3 25 | $432.3M | $1.4B | ||
| Q2 25 | $444.3M | $1.5B | ||
| Q1 25 | $489.6M | $1.5B | ||
| Q4 24 | $491.1M | $1.5B | ||
| Q3 24 | $477.0M | $1.5B | ||
| Q2 24 | $466.8M | $1.5B |
负债/权益比CDNAROG
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $1.1M |
| 自由现金流率自由现金流/营收 | 0.4% | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | 1.54× | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流CDNAROG
| Q1 26 | $4.3M | $5.8M | ||
| Q4 25 | $21.4M | $46.9M | ||
| Q3 25 | $37.4M | $28.9M | ||
| Q2 25 | $9.9M | $13.7M | ||
| Q1 25 | $-26.6M | $11.7M | ||
| Q4 24 | $21.9M | $33.7M | ||
| Q3 24 | $12.5M | $42.4M | ||
| Q2 24 | $18.9M | $22.9M |
自由现金流CDNAROG
| Q1 26 | $514.0K | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率CDNAROG
| Q1 26 | 0.4% | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | — | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度CDNAROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率CDNAROG
| Q1 26 | 1.54× | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | 22.30× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
ROG
暂无分部数据
